- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06875648
Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals
Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals: A Case-Control Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Guangdong
-
Zhanjiang, Guangdong, China, 524002
- Central Hospital of Guangdong Provincial Nongken
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (≥18 years) with histopathologically confirmed colorectal cancer (CRC group)
- Archived fecal sample available from time of CRC diagnosis (prior to treatment)
- Complete clinical records including TNM staging (I-III) for CRC patients
- Age- and gender-matched adults without CRC history (control group)
- Archived fecal sample available from routine health check-ups (control group)
Exclusion Criteria:
- Recent antibiotic or probiotic use (within 3 months)
- History of inflammatory bowel disease
- Incomplete medical records
- For controls: history of colorectal cancer, polyps, or chronic gastrointestinal diseases
- For controls: abnormal colonoscopy or fecal occult blood test within the past year
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
CRC Patients
Participants: 36 individuals with histopathologically confirmed colorectal cancer. Data Source: Archived fecal samples and medical records from patients diagnosed between January 2022 and October 2023. Inclusion Criteria: Adults (≥18 years). Newly diagnosed CRC without prior chemotherapy/radiotherapy. Availability of fecal samples collected at diagnosis. Exclusion Criteria: Antibiotic/probiotic use within 3 months before sample collection. Concurrent gastrointestinal infections or inflammatory bowel disease. Subgroups: Stratified by clinical stage (I, II, III) based on TNM classification from medical records. |
Retrospective analysis of gut microbiota in CRC patients vs. healthy controls.
No interventions were administered; data were collected from archived samples and medical records.
|
|
Healthy Controls
Participants: 25 age- and gender-matched individuals without gastrointestinal diseases or cancer history. Data Source: Archived fecal samples and health screening records from routine check-ups during the same period. Inclusion Criteria: Adults (≥18 years). No history of colorectal polyps, cancer, or chronic gastrointestinal disorders. Normal colonoscopy or fecal occult blood test results. Exclusion Criteria: Antibiotic/probiotic use within 3 months before sample collection. Recent acute gastrointestinal symptoms (e.g., diarrhea, constipation). |
Retrospective analysis of gut microbiota in CRC patients vs. healthy controls.
No interventions were administered; data were collected from archived samples and medical records.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Mean Relative Abundance of Intestinal Bacterial Genera between CRC Patients and Healthy Controls
Time Frame: Retrospective analysis of fecal samples collected between January 2021 and March 2025
|
The primary metric is the mean relative abundance of specific intestinal bacterial genera (e.g., Lactobacillus, Bifidobacterium, Staphylococcus).
Quantitative comparison will be performed between CRC patients and healthy controls using data obtained from fecal samples via 16S rRNA sequencing or qPCR.
This is a retrospective analysis of samples collected between January 2021 and March 2025.
|
Retrospective analysis of fecal samples collected between January 2021 and March 2025
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GDMEC-2024-028
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.